Whalesbook
📉 The Financial Deep Dive
Marksans Pharma has announced a strong performance for the third quarter of FY26, driven by record operating revenue and enhanced profitability. The company posted an all-time high quarterly operating revenue of ₹754.4 crores, marking a significant 10.6% year-on-year (YoY) increase. This growth was primarily fueled by the U.S. and North America, which saw a robust 16.9% YoY jump in revenue to ₹412.4 crores, and a commendable 30.1% YoY rise from Australia and New Zealand.
Gross profit climbed 14.3% YoY to ₹438.2 crores, with gross margins expanding by 184 basis points to a healthy 58.1%. This improvement is attributed to favourable raw material prices, a better product mix, and positive foreign exchange movements.
EBITDA surged by 23.2% YoY to ₹160.7 crores, translating into an expanded EBITDA margin of 21.3%, up 217 basis points from the previous year. This gain reflects operational leverage and effective cost efficiencies. Profit After Tax (PAT) saw an 8.2% YoY increase to ₹113.7 crores, with Earnings Per Share (EPS) at ₹2.5 for the quarter.
For the nine-month period (9M) of FY26, operating revenue grew 9.4% YoY to ₹2,094.8 crores, with the U.S. market alone contributing ₹1,127.3 crores (up 24.2% YoY). While 9M gross margins improved marginally by 43 bps to 57.7%, the 9M EBITDA margin stood at 19.4%, lower than 21.2% in 9M FY25, which management attributes to a weaker Q1, higher employee expenses, and costs associated with scaling up operations.
💰 Financial Deep Dive & Cash Flow
The company continues its strong financial footing by remaining entirely debt-free. As of December 31, 2025, Marksans Pharma held a substantial cash balance of ₹824.2 crores across its subsidiaries. Operating cash flow for the first nine months of FY26 was ₹263.2 crores, while capital expenditure (CapEx) stood at ₹97 crores. R&D investments were maintained at approximately 3% of consolidated revenue.
🚀 Outlook & Management Commentary
Management anticipates significant growth, projecting the U.S. market to rebound with around 20% growth in the upcoming fiscal year, supported by an order book exceeding $220 million. The U.K. market is showing signs of stabilization, bolstered by new product approvals from the MHRA (Medicines and Healthcare products Regulatory Agency) for mefenamic acid tablets and cetirizine oral solutions.
A key strategic focus is geographic expansion into Europe. Marksans has incorporated subsidiaries in Ireland (Marksans Europe Limited) and Canada (Marksans Canada Inc.) and is actively exploring M&A opportunities. The company aims for substantial progress and contribution from Europe within the next 3-5 years, with potential M&A deals expected to materialize in the next 3-4 months. Revenue targets are ambitious, aiming for INR 4,000 crores within the next 2-3 years, with a subsequent milestone of INR 5,000 crores.
Challenges such as elevated employee costs due to the Goa facility and new labor code accounting are being addressed, with management expecting these costs as a percentage of sales to decline by Q2 of the next financial year.
🚩 Risks & The Forward View
The primary risk identified is the persistent pricing pressure in the U.K. and E.U. markets, although management believes this erosion is nearing its bottom. The lower 9M EBITDA margin compared to the previous year warrants monitoring, despite Q3's strong rebound. Execution risk associated with aggressive M&A plans in Europe also remains a key area for investors to watch. The company's ability to integrate new acquisitions and navigate complex European regulatory landscapes will be crucial. Investors should monitor progress on European M&A, the growth trajectory of the U.S. market, and the stabilization of margins in the U.K. and E.U. over the next 1-2 quarters.